Arcturus therapeutics receives orphan medicinal product designation from the european commission (ec), for arct-032, for the treatment of cystic fibrosis

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the european commission (ec), based on a positive opinion issued by the european medicines agency (ema), has granted orphan medicinal product designation for the com.
ARCT Ratings Summary
ARCT Quant Ranking